[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8oVG4_zs3SYdoGObJMv-lyYc5CK-drDizAMe7LqZkW4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer",[4],75,false,22,3,22179,1,68,[14,16,18,21,23,25,27,29],{"name":15,"count":9},"Pulmonary Embolism",{"name":17,"count":9},"Chronic Obstructive Pulmonary Disease (COPD)",{"name":19,"count":20},"Deep Vein Thrombosis",2,{"name":22,"count":20},"Covid-19",{"name":24,"count":20},"COVID-19",{"name":26,"count":20},"Drug Use",{"name":28,"count":20},"Respiratory Distress Syndrome",{"name":30,"count":11},"Sleep Fragmentation",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06552234","Phase II Efficacy Study of Repotrectinib in Frail and\u002For Elderly Patients With ROS1-rearranged Advanced NSCLC","2031-09","Repotrectinib",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,69,95,113,140,158,183,201,226,252,270],{"intervention":36,"totalTrials":11,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":63,"PHASE4":65,"NA":67},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":11,"soonestReadout":35},[54],{"nctId":33,"briefTitle":34,"status":55,"phases":56,"primaryCompletion":35,"completion":35,"start":57,"enrollment":58,"conditions":59,"interventions":62},"RECRUITING",[40],"2024-10-01",30,[60,61],"NSCLC Stage IV","NSCLC, Stage III",[36],{"trials":64,"activeCount":49},[],{"trials":66,"activeCount":49},[],{"trials":68,"activeCount":49},[],{"intervention":70,"totalTrials":11,"cells":71},"Sodium Oxybate",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":93},{"trials":73,"activeCount":49},[],{"trials":75,"activeCount":49},[],{"trials":77,"activeCount":49},[],{"trials":79,"activeCount":49},[],{"trials":81,"activeCount":49},[82],{"nctId":83,"briefTitle":84,"status":85,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":8,"conditions":89,"interventions":91},"NCT05085873","Sodium Oxybate Versus Midazolam for Comfort Sedation","COMPLETED",[42],"2023-10-10","2021-10-14",[90],"Palliative Care",[70,92],"Midazolam",{"trials":94,"activeCount":49},[],{"intervention":92,"totalTrials":11,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":111},{"trials":98,"activeCount":49},[],{"trials":100,"activeCount":49},[],{"trials":102,"activeCount":49},[],{"trials":104,"activeCount":49},[],{"trials":106,"activeCount":49},[107],{"nctId":83,"briefTitle":84,"status":85,"phases":108,"primaryCompletion":87,"completion":87,"start":88,"enrollment":8,"conditions":109,"interventions":110},[42],[90],[70,92],{"trials":112,"activeCount":49},[],{"intervention":114,"totalTrials":11,"cells":115},"Isentress®",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":136,"NA":138},{"trials":117,"activeCount":49},[],{"trials":119,"activeCount":49},[],{"trials":121,"activeCount":49},[],{"trials":123,"activeCount":49},[124],{"nctId":125,"briefTitle":126,"status":85,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT00935480","IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +\u002F- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients",[41],"2010-11-12","2014-08-08","2010-10",17,[133],"HIV Infections",[114,135],"Celsentri®",{"trials":137,"activeCount":49},[],{"trials":139,"activeCount":49},[],{"intervention":135,"totalTrials":11,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":154,"NA":156},{"trials":143,"activeCount":49},[],{"trials":145,"activeCount":49},[],{"trials":147,"activeCount":49},[],{"trials":149,"activeCount":49},[150],{"nctId":125,"briefTitle":126,"status":85,"phases":151,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":152,"interventions":153},[41],[133],[114,135],{"trials":155,"activeCount":49},[],{"trials":157,"activeCount":49},[],{"intervention":159,"totalTrials":11,"cells":160},"Anakinra alone",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":177,"PHASE4":179,"NA":181},{"trials":162,"activeCount":49},[],{"trials":164,"activeCount":49},[],{"trials":166,"activeCount":49},[167],{"nctId":168,"briefTitle":169,"status":170,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":20,"conditions":174,"interventions":175},"NCT04366232","Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation","TERMINATED",[40],"2020-10-02","2020-08-19",[22],[159,176],"Anakinra and Ruxolitinib",{"trials":178,"activeCount":49},[],{"trials":180,"activeCount":49},[],{"trials":182,"activeCount":49},[],{"intervention":176,"totalTrials":11,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":195,"PHASE4":197,"NA":199},{"trials":186,"activeCount":49},[],{"trials":188,"activeCount":49},[],{"trials":190,"activeCount":49},[191],{"nctId":168,"briefTitle":169,"status":170,"phases":192,"primaryCompletion":172,"completion":172,"start":173,"enrollment":20,"conditions":193,"interventions":194},[40],[22],[159,176],{"trials":196,"activeCount":49},[],{"trials":198,"activeCount":49},[],{"trials":200,"activeCount":49},[],{"intervention":202,"totalTrials":11,"cells":203},"Samples",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":205,"activeCount":49},[],{"trials":207,"activeCount":49},[],{"trials":209,"activeCount":49},[],{"trials":211,"activeCount":49},[],{"trials":213,"activeCount":49},[],{"trials":215,"activeCount":49},[216],{"nctId":217,"briefTitle":218,"status":85,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT03497481","Neopterin Dosage in the Eye",[],"2019-01-25","2018-06-22",20,[224],"Cataract",[202],{"intervention":227,"totalTrials":11,"cells":228},"PENG Block",{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":230,"activeCount":49},[],{"trials":232,"activeCount":49},[],{"trials":234,"activeCount":49},[],{"trials":236,"activeCount":49},[],{"trials":238,"activeCount":49},[],{"trials":240,"activeCount":49},[241],{"nctId":242,"briefTitle":243,"status":85,"phases":244,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT05673486","Regional Anesthesia by PENG-Block in Emergency Department",[43],"2023-12-25","2023-03-31",36,[249],"Hip Fractures",[227,251],"Multimodal analgesia",{"intervention":251,"totalTrials":11,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":255,"activeCount":49},[],{"trials":257,"activeCount":49},[],{"trials":259,"activeCount":49},[],{"trials":261,"activeCount":49},[],{"trials":263,"activeCount":49},[],{"trials":265,"activeCount":49},[266],{"nctId":242,"briefTitle":243,"status":85,"phases":267,"primaryCompletion":245,"completion":245,"start":246,"enrollment":247,"conditions":268,"interventions":269},[43],[249],[227,251],{"intervention":271,"totalTrials":11,"cells":272},"Iatrogenic disease impact on emergency consultations",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":274,"activeCount":49},[],{"trials":276,"activeCount":49},[],{"trials":278,"activeCount":49},[],{"trials":280,"activeCount":49},[],{"trials":282,"activeCount":49},[],{"trials":284,"activeCount":49},[285],{"nctId":286,"briefTitle":287,"status":85,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":294},"NCT03960398","Incidence of Iatrogenic Diseases on Hospital's Emergency Consultations",[],"2019-09-09","2019-06-28",2500,[293],"Iatrogenic Disease",[271]]